Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith

SOTIO Biotech’s CSO explains why drug developers should test their weakest assumptions early, how she builds innovative teams, and where ADCs could go next

October 12, 2026
9 min

The Medicine Maker

1

As SOTIO Biotech’s chief scientific officer, Amy Jensen-Smith oversees preclinical antibody-drug conjugate programs for solid tumors, from target and technology discovery to clinical readiness.
2

Jensen-Smith said her move from bench science to leadership let her consider broader implications of discoveries while continuing to do science and build teams.
3

For new targets, SOTIO identifies the program’s most critical uncertainty and tests it early to determine whether the idea is worth pursuing.
4

Jensen-Smith described biotech as offering a balance of resources, technology, focus, and freedom for innovative research, based on her experience.
5

She advises scientific leaders to hire people with different backgrounds and work styles, make failure acceptable, and listen to team members’ ideas.

Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith

1

2

3

4

5

Original Source(s)

Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith

Related Content

What Medicare Claims Tell Us About Cancer Disparities in American Indian and Alaska Native Peoples

2026 ASCO Breast Cancer Highlights: SENOMAC

Building a Pre-Disease Data Map